Ther­at­e­ch­nolo­gies hit with FDA refuse to file let­ter for in­tra­mus­cu­lar ver­sion of HIV drug

Ther­at­e­ch­nolo­gies was hit with a sec­ond set­back from the FDA this year as the agency hand­ed down a refuse to file let­ter for the com­pa­ny’s in­tra­mus­cu­lar ver­sion of its HIV drug Trog­a­r­zo.

The Mon­tre­al-based biotech said Tues­day that the FDA re­fused to file its sBLA for Trog­a­r­zo be­cause its Jan­u­ary fil­ing wasn’t “suf­fi­cient­ly com­plete” and “did not con­tain the da­ta re­quired to es­tab­lish the phar­ma­co­ki­net­ic bridge” be­tween the in­tra­mus­cu­lar and in­tra­venous ad­min­is­tra­tion of the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER